(2026). Pooled survival and cost-effectiveness analysis of immune checkpoint inhibitors-based for metastatic non-small-cell lung cancer with PD-L1 lower than 1%. Health Economics Review.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Pooled Survival and Cost-effectiveness Analysis of Immune Checkpoint Inhibitors-based for Metastatic Non-small-cell Lung Cancer with PD-L1 Lower than 1%."
Health Economics Review 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Pooled Survival and Cost-effectiveness Analysis of Immune Checkpoint Inhibitors-based for Metastatic Non-small-cell Lung Cancer with PD-L1 Lower than 1%."
Health Economics Review, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.